Nanjing Novozen Medical Technology Co., Ltd. was established in 2016 and is a national high-tech enterprise. It focuses on the research and development, production, sales and service of in vitro diagnostic reagents and instruments. Its products cover cardiovascular and cerebrovascular diseases, prenatal and postnatal care, tumor, renal function, infection, children's respiratory tract and other fields. It is one of the enterprises with the most comprehensive POCT product line in China. Its central cerebrovascular diagnostic products are aimed at the construction of the domestic chest pain center and provide the best solution. It is the most comprehensive enterprise in the series of products in China. In 2018, Novozem was successfully listed on the Forbes list of potential enterprises of unlisted companies, and the first batch of Nanjing enterprises to cultivate "unicorns" and "gazelles" were listed.
